Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Definitively Does not Deserve Its Bad Reputation

Überrück L, Nadiradze G, Yurttas C, et al. In-hospital mortality and complication rates according to health insurance data in patients undergoing hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies in Germany. Ann Surg Oncol. Epub ahead of print November 9, 2020. https://doi.org/10.1245/s10434-020-09301-z. Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13. Piso P, Nedelcut SD, Rau B, et al. Morbidity and mortality following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: data from the DGAV StuDoQ registry with 2149 consecutive patients. Ann Surg Oncol. 2019;26:148–54. Noiret B, Clement G, Lenne X, et al. Centralization and oncologic training reduce postoperative morbidity and failure-to-rescue rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: study on a 10-year national French practice. Ann Surg. Epub ahead of print August 21, 2020. https://doi.org/10.1097/SLA.0000000000004326. El Amrani M, Lenne X, Clement G, et al. Specificity of procedure volume and its association with postoperative mortality in digestive cancer surgery: a nationwide study of 225,752 patients. Ann Surg. 2019;270:775–82.